BioCryst Pharma (BCRX) Tops Q2 EPS by 11c, provides product guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq set for higher open as oil prices extend declines, midterm results awaited
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.29 +0.61%
Revenue Growth %: +3.9%
Financial Fact:
Basic and diluted net loss per common share: -0.16
Today's EPS Names:
INM, TRI, CRVL, More
Revenue Growth %: +3.9%
Financial Fact:
Basic and diluted net loss per common share: -0.16
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of ($0.06), $0.11 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $109.33 million versus the consensus estimate of $98.3 million.
Guidance:
Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)—
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Exclusive: OwlTing CEO on scaling Harbor, growth and path to profitability
- Dell Technologies stock climbs after AI security deal
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
